TREATMENT OF CANCER WITH HEAVY CHARGED PARTICLES

为了测试改进剂量分布(氦)的潜在优势 改善了剂量分布，增加了生物效应(霓虹灯， 硅，氩)，正在进行一项临床试验，以研究治疗 这些重带电粒子在人类癌症治疗中的应用。 分割、大野、布喇格峰值带电粒子放射治疗 治疗技术正在不断地改进和改进 组织匀质性利用中的评估和补偿技术 CT扫描仪以获得粒子束路径中的组织密度。 已经制定了几个使用氦的试验方案，到目前为止只有一个 随机试验：氦离子治疗加5-FU与常规放射治疗 治疗加5-FU。我们还启动了第一至第二阶段的试点研究， 较重的离子，如碳、霓虹和氩。我们的最终目标是测试 一项随机试验中重带电粒子与最佳可用治疗方法的对比 精选出的肿瘤。现有的合作研究小组，如辐射 治疗肿瘤学小组和北加州肿瘤学小组正在 用于促进这些试验，与旧金山湾区重离子 协会。

In order to test the potential advantages of improved dose distribution (helium) and both improved dose distribution and increased biological effect (neon, silicon, argon), a clinical trial is being conducted to study the therapeutic application of these heavy charged particles in the treatment of human cancers. Fractionated, large field, spread out Bragg peak charged particle radiotherapy treatment techniques are being continually refined together with improved techniques for assessment and compensation of tissue in homogeneities utilizing CT scanners to obtain tissue densities in the particle beam paths. Several pilot protocols with helium have been instituted, leading so far to one randomized trial: helium ion treatment plus 5-FU versus conventional radiation therapy plus 5-FU. We have also instituted Phase I-II pilot studies with heavier ions such as carbon, neon, and argon. Our ultimate goal is to test heavy charged particles against the best available therapy in a randomized trial of selected tumors. Existing cooperative study groups such as the Radiation Therapy Oncology Group and the Northern California Oncology Group are being utilized to facilitate these trials, together with the Bay Area Heavy Ion Association.